AC
CYCN icon

AWH Capital’s Cyclerion Therapeutics CYCN Stock Holding History

AWH Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,620
Closed -$310K – 47
2020
Q2 		$310K Sell
2,620
-13,630
-84% -$1.14M 0.61% 28
2020
Q1 		$861K Sell
16,250
-13,250
-45% -$945K 4.66% 7
2019
Q4 		$1.6M Buy
29,500
+28,355
+2,476% +$2.65M 1.87% 17
2019
Q3 		$278K Buy
1,145
+640
+127% +$138K 0.35% 24
2019
Q2 		$116K Buy
+505
New +$143K 0.17% 23

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AWH Capital's CYCN Position: Q3 2020 in Review

AWH Capital sold out of Cyclerion Therapeutics (CYCN) in Q3 2020, closing a stake of 2,620 shares — an estimated $310K sold.

AWH Capital first reported a position in CYCN in Q2 2019 and held it in 5 quarters. The position peaked at $1.6M in Q4 2019. 73 funds tracked by Wall St. Rank hold CYCN as of Q3 2020.

  • AWH Capital reported no remaining Cyclerion Therapeutics position as of Q3 2020 after selling out during the quarter.
  • AWH Capital sold 2,620 Cyclerion Therapeutics shares in Q3 2020, an estimated $310K.
  • AWH Capital first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 5 quarters.
  • AWH Capital's Cyclerion Therapeutics position peaked at $1.6M in Q4 2019.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2020.

Based on AWH Capital's 13F filing for Q3 2020, filed 16 Nov 2020.